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of the jaw
ABSTRACT
The relationship between osteonecrosis of the jaw and bisphosphonate therapy has been described 
recently. Although bisphosphonates have a  long list of benefits in the treatment of patients with bone 
metastases, an increasing number of reports describe the complication of bisphosphonate-related os-
teonecrosis of the jaw (BRONJ). Bisphosphonates are synthetic analogues of pyrophosphate that inhibit 
bone resorption. The aetiology of BRONJ is unclear. It starts as aseptic necrosis, with a surgical procedure 
involving an interruption in the continuity of the oral mucosa as an obligatory precondition. Subsequently, 
areas of osteonecrosis occur and detach from the surrounding areas of purulent inflammation or can be 
removed surgically. Due to the limited treatment options, conservative treatment supported by antibiotic 
and surgical therapy is used. This article describes a case of BRONJ. 
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Introduction 
Bisphosphonates are medicines useful in patients 
with bone metastases originating in primary breast, 
prostate and kidney cancers, multiple myeloma and 
Paget’s disease [1]. Bisphosphonates are also used 
by patients with osteoporosis [2, 3].
The multi-directional activity of these drugs with their 
inhibitory effect on bone resorption has many benefits 
but is also burdened by adverse effects [4]. A particular 
adverse effect affecting the oral cavity is bisphospho-
nate-related osteonecrosis of the jaw (BRONJ). 
It is defined as an area of exposed bone in the max-
illofacial region which does not heal within 8 weeks in 
a patient currently or previously treated with bisphos-
phonates and not subjected to radiation therapy of the 
head or neck [5, 6, 7]. 
The disease is mainly associated with intravenous ad-
ministration of high doses of bisphosphonates, but cases 
of BRONJ in patients treated with low oral doses have also 
been observed [8]. Treatment and prosthetic rehabilitation 
of the affected patients are difficult and very limited.
Case description
A patient receiving treatment for breast cancer. In 
1997, right-side mastectomy was conducted due to 
cancer, followed by chemotherapy and radiation thera-
py. In 2002, a local recurrence was detected along with 
metastases to the spine and the supra- and infraclavic-
ular lymph nodes on the right side. In 2005, metastases 
to the shoulder tissues were detected. Type 2 diabetes 
mellitus. The patient was treated with bisphosphonates 
between July 2002 and May 2017. Treatments used 
include, inter alia, clodronic acid, 90 mg every 4 weeks, 
i.v. (Jul 2002–Oct 2005), pamidronic acid, 60 mg every 
4 weeks, i.v. (Nov 2005–Feb 2011), zoledronic acid, 
4 mg every 4 weeks, i.v. (Mar 2011–May 2017). In 2011, 
the patient underwent maxillary tooth extractions. The 
alveoli were not closed with stitches. Not all post-ex-
traction wounds healed, and osteonecrosis occurred 
in the incisor area. The patient was hospitalized several 
times due to pain in the area. In January 2018, maxillo-
facial CT with contrast revealed “loss of the right-side 
alveolar process of approx. 30×16×17 mm without 
separation of pathological mass — necrosis?” (Fig. 1). 
In April 2018, the patient reported pain in the area and 
leakage of fluid through the nose during drinking. In physical 
examination, exposed right-side maxillary alveolar process 
between the alveoli for teeth 11 to 13, reaching the vestibular 
fornix (Fig. 2). Increased oral hygiene recommended. 
Discussion
In terms of chemical structure, bisphosphonates 
are synthetic analogues of pyrophosphate (natural 
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regulator of bone mineralization) in which the central 
oxygen atom has been replaced by a  carbon atom. 
Two additional side chains R1 and R2 are bound to the 
carbon atom. R1 is usually a hydroxyl group. Depending 
on the composition of R2, bisphosphonates can be 
divided into two major groups:
1. Simple (non-nitrogenous) bisphosphonates — with-
out nitrogen in the R2 composition.
2. Nitrogenous bisphosphonates (aminobisphospho-
nates) — containing nitrogen in the R2 composition, 
including alendronate, zoledronate, pamidronate, 
risedronate, ibandronate [9, 10].
Bisphosphonates have a high affinity to hydroxyapa-
tite crystals in bone, which they bind via two phosphate 
groups and the R1 side chain that together form the 
“bone hook” 11].
Aminobisphosphonates with a long side chain con-
taining nitrogen cause disruption of the osteoclast intra-
cellular signalling system, which results in the inhibition 
of the metabolic activity of mature osteoclasts. The 
clinical effect of aminobisphosphonates is inhibition of 
bone resorption [9]. 
Approximately 60% of the administered dose is de-
posited in areas of active bone mineralization, and its 
half-life is approximately 10 years. The non-deposited 
fraction is excreted by the kidneys [8]. The aetiology 
of BRONJ is unclear. It is caused by the exposure of 
maxillary or mandibular bone due to an interruption in 
Figure 1. Current CT image — red arrows indicate a bone loss in the maxilla
Figure 2. The current image of alveoli
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the continuity of the mucosa, e.g., during dental pro-
cedures or as a sequela of denture-related sores [10]. 
Because of the constantly applied pressures asso-
ciated with chewing, the mandible and the maxilla are 
characterized by a greater bone turnover than other 
skeletal regions (e.g., 10–20 times greater than in the 
ilium) [12]. This intensity of bone turnover is necessary 
to repair microfractures arising during chewing. Con-
currently, it requires a higher degree of vascularization, 
which is crucial in bisphosphonate therapy, allowing 
a higher concentration of these drugs in the bone tissue 
in that area [13]. The oral mucosa is thin and susceptible 
to damage, which facilitates bacterial infection of the 
exposed bone [14, 15].
Maxillary BRONJ leads to the formation of osteone-
crotic areas. The disease presents similarity to radiation 
therapy-induced osteonecrosis, starting as aseptic 
necrosis of bone. Aseptic necrosis is usually caused 
by insufficient blood supply [16, 17]. 
In recent years, it was noted that similar lesions 
can occur in patients after treatment with denosumab 
(anti-RANKL IgG2) and bevacizumab (anti-VEGF an-
tibody reducing tumour vasculature) [18], regardless 
of previous bisphosphonate therapy. There is also 
a number of factors that increase the risk of BRONJ. 
Among them, in the course of multiple myeloma, a likely 
genetic factor can be distinguished — polymorphism of 
the CYP2C8 gene that is linked to the arachidonic acid 
cycle and is a regulator of vascularization, which in the 
mandible could lead to poorer vascularity and increased 
risk of BRONJ (up to 12.5 times) [19]. 
Other BRONJ risk factors include glucocorticoste-
roids (chronic therapy adversely affects bone metabo-
lism, weakening osteoblast differentiation and function). 
Furthermore, the immunosuppressive and antiangio-
genic effect of glucocorticoids can play a major role in 
the development of necrosis [20–22]. 
The frequency of BRONJ increases from 1.5% (in 
patients treated for 4–12 months) to 7.7% (in patients 
treated for 37–48 months) [23]. 
The risk of this disease can also be increased by 
[24]: High alcohol consumption, smoking, anemia, 
chemotherapy, diabetes mellitus, obesity, renal failure, 
rheumatoid arthritis, immunosuppression, older age 
(risk increases by 9% per decade of life), female gender 
(maxillary BRONJ is 8 times more frequent in women 
than in men).
Local factors include [20] anatomical structures 
involving compact bone covered by a thin layer of muco-
sa, such as bony prominences or tubercles, periodontal 
diseases, including spontaneous tooth loss, surgical 
interventions related to the interruption in the continuity 
of oral mucosa, such as tooth extractions, periodontal 
treatments (scaling, curettage), placement of dental 
implants, endodontic therapy (when the tool is moved 
beyond the tip of the tooth root), misfitted dentures, 
poor oral hygiene.
The disease is usually diagnosed clinically. As 
a result of the lack of healing, areas of osteonecrosis 
occur and detach from the surrounding areas of pu-
rulent inflammation. The process is accompanied by 
pain, numbness, soft tissue oedema, hyperesthesia, 
tooth loosening, suppuration, and intra- and extra-
oral fistulas. Although these symptoms can develop 
spontaneously, BRONJ is much more frequent after 
surgical interventions on alveolar processes involving 
an interruption in the continuity of the mucosa and 
periodontium [8]. 
In some cases, necrosis develops asymptomatically 
and is clinically undetectable, with the patient being 
unaware of the disease for weeks or months. The first 
symptoms preceding clinically developed necrosis 
can include pain, mucosal ulceration, erythema and 
oedema, and tooth loosening [20]. In maxillary BRONJ, 
abscesses can reach the supra canine and buccal 
spaces [25]. In mandibular BRONJ, abscesses can be 
located in the submental, submandibular and sublingual 
spaces [26]. The difference in compactness between 
the maxilla and the mandible causes a different course 
of inflammation in these bones. In the maxilla, suppu-
ration is manifested by a fistula, while in the mandible, 
suppuration spreads within the bone and rarely reaches 
its surface [27]. 
Three stages of progression of BRONJ have been 
distinguished [28]. 
Stage I — exposure of bone without oedema and 
erythema of the surrounding soft tissue, without radio-
logical changes; pain can occur before bone exposure.
Stage II — primary or secondary inflammation of 
the soft tissue surrounding the exposed bone, pain, 
tooth loosening. Necrotic lesions in the radiological 
image can resemble periapical radiolucency, broad-
ening of the periodontium or thickening of the alveolar 
lamina dura.
Stage II — primary or secondary inflammation of the 
soft tissue which is difficult to treat with oral or intravenous 
antibiotic therapy; the presence of extraoral fistulas. If the 
lesion affects the mandible, hypoesthesia of the lower lip 
can occur, and when the maxilla is affected, secondary 
maxillary sinusitis can develop. In the radiological image, 
a visible increase in radiolucency, pathological fractures 
of the mandible, necrotic areas, as well as osteitis-like 
and metastasis-like lesions can be found.
As has been reported in the literature, bacteriological 
tests can reveal the presence of Staphylococcus epider-
midis, Streptococcus salivarius, Morganella morganii, 
Prevotella intermedia and Prevotella oris, as well as 
Escherichia coli — Gram-negative rods. In half of the 
cases, the exposed bone is colonized by Actinomyces 
strains [29]. 
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Table 1. Methods of treatment of BRONJ [4]: 
Stage of 
progression
Definition Treatment
Stage I — Loss of oral mucosa with bone exposure which can be preceded by 
pain
— No radiological signs
— No features of infection, edema or soft tissue erythema
Conservative (flushing of the oral 
cavity with, e.g., 0.12% chlorhexidine 
solution)
Stage II — Loss of oral mucosa with bone exposure
— Clinical features of infection
— Soreness, tooth loosening
— In X-ray, increased radiolucency, thickening of the alveolar lamina 
dura
Conservative (flushing of the oral 
cavity with, e.g., 0.12% chlorhexidine 
solution, and 
antibiotic/antifungal therapy)
Stage III — Loss of oral mucosa with bone exposure
— Clinical features of infection with pain
— Signs, such as: fistula, pathological fracture, osteolysis, impaired 
sensation, sinusitis  
— In X-ray, increased radiolucency, necrotic areas, osteitis 
— Surgical (resection of necrotic 
tissue or resection with 
vascularized bone grafting)
— Antibiotic/antifungal therapy 
The diagnosis of BRONJ is based on anamnesis, 
physical examination, clinical presentation and diagnos-
tic imaging, usually pantomography or CT.
Treatment of patients with BRONJ is difficult. Treat-
ment methods depending on the stage of progression 
and the extent of necrosis are shown in Table 1. 
Conclusions
BRONJ is an increasingly observed complication fol-
lowing treatment procedures in the oral cavity of patients 
concurrently or previously receiving bisphosphonates. It 
is a very painful disease that is difficult to treat. Dental 
practitioners should be made more aware of the need 
for detailed anamnesis before conducting procedures 
that involve an interruption in the continuity of the oral 
mucosa. Previous treatment of oral problems in patients 
beginning bisphosphonate therapy, greater awareness 
of the need to inform the dentist of all medications taken 
currently and, in the past, as well as periodic checks and 
stricter hygiene regime might contribute to a reduction 
in the frequency of this complication.
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